PLANEGG/MUNICH, GERMANY / ACCESSWIRE / December 27, 2019 / MorphoSys AG (FSE:MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ:MOR) today announced that the first patient has been dosed in a phase 1b clinical study of MorphoSys' proprietary human anti-CD19 antibody tafasitamab in newly diagnosed diffuse large B cell lymphoma (DLBCL). The phase 1b study is an open-label, randomized, multicenter study to evaluate safety and preliminary efficacy of tafasitamab in addition to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristin, prednison) as well as tafasitamab and lenalidomide in addition to R-CHOP in adult patients with newly diagnosed, previously untreated DLBCL. Patients enrolled in each arm will receive six cycles of treatment. The primary endpoint is the incidence and severity of treatment-emergent adverse events (AEs), key secondary endpoints are objective response rate (ORR) and PET-negative complete response (CR) rate at the end of treatment.

"It is a great opportunity for us to expand the clinical development of tafasitamab into firstline DLBCL," said Dr. Malte Peters, Chief Development Officer of MorphoSys. "Based on the encouraging results we have seen so far with tafasitamab in relapsed and refractory DLBCL, we are now looking forward to explore the potential of tafasitamab in addition to R-CHOP or lenalidomide and R-CHOP in newly diagnosed DLBCL. This phase 1b study forms the basis for a subsequent pivotal phase 3 study in front line DLBCL. DLBCL is an aggressive and very challenging disease and we hope to improve the current R-CHOP standard of care by adding tafasitamab and lenalidomide to offer a potential new treatment option for these critically ill patients."

About tafasitamab (MOR208)

Tafasitamab (formerly MOR208) is an investigational humanized Fc-engineered monoclonal antibody directed against CD19. Fc-modification of tafasitamab is intended to lead to a significant potentiation of antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP), thus aiming to improve a key mechanism of tumor cell killing. Tafasitamab has been observed in preclinical models to induce direct apoptosis by binding to CD19, which is assumed to be involved in B cell receptor (BCR) signaling.
MorphoSys is clinically investigating tafasitamab as a therapeutic option in B cell malignancies in a number of ongoing combination trials. An open-label phase 2 combination trial (L-MIND study) is investigating the safety and efficacy of tafasitamab in combination with lenalidomide in patients with relapsed/refractory DLBCL who are not eligible for high-dose chemotherapy (HDC) and autologous stem cell transplantation (ASCT). Based on interim data from L-MIND, in October 2017 the U.S. FDA granted Breakthrough Therapy Designation for tafasitamab plus lenalidomide in this patient population. B-MIND is a phase 3 study assessing the combination of tafasitamab and bendamustine versus rituximab and bendamustine in r/r DLBCL. In addition, tafasitamab is currently being investigated in patients with relapsed/refractory CLL/SLL after discontinuation of a prior Bruton tyrosine kinase (BTK) inhibitor therapy (e.g. ibrutinib) in combination with idelalisib or venetoclax.

About MorphoSys

MorphoSys (FSE & NASDAQ: MOR) is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of exceptional, innovative therapies for patients suffering from serious diseases. The focus is on cancer. Based on its leading expertise in antibody, protein and peptide technologies, MorphoSys, together with its partners, has developed and contributed to the development of more than 100 product candidates, of which 28 are currently in clinical development. In 2017, Tremfya(R), marketed by Janssen for the treatment of plaque psoriasis, became the first drug based on MorphoSys's antibody technology to receive regulatory approval. The Company's most advanced proprietary product candidate, tafasitamab (MOR208), has been granted U.S. FDA breakthrough therapy designation for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Headquartered near Munich, Germany, the MorphoSys group, including the fully owned U.S. subsidiary MorphoSys US Inc., has approximately 405 employees. More information at https://www.morphosys.com.

HuCAL(R), HuCAL GOLD(R), HuCAL PLATINUM(R), CysDisplay(R), RapMAT(R), arYla(R), Ylanthia(R), 100 billion high potentials(R), Slonomics(R), Lanthio Pharma(R), LanthioPep(R) and ENFORCERTM are trademarks of the MorphoSys Group. Tremfya(R) is a trademark of Janssen Biotech, Inc.

MorphoSys forward looking statements

This communication contains certain forward-looking statements concerning the MorphoSys group of companies, including the expectations regarding the clinical development of tafasitamab in previously untreated DLBCL, in combination with lenalidomide in the L-MIND study in r/r DLBCL, the clinical development of tafasitamab in combination with bendamustine versus rituximab and bendamustine in the B-MIND study in r/r DLBCL, the further clinical development of tafasitamab as well as interactions with regulatory authorities and expectations regarding regulatory filings and possible approvals for tafasitamab. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve known and unknown risks and uncertainties, which might cause the actual results, financial condition and liquidity, performance or achievements of MorphoSys, or industry results, to be materially different from any historic or future results, financial conditions and liquidity, performance or achievements expressed or implied by such forward-looking statements. In addition, even if MorphoSys' results, performance, financial condition and liquidity, and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. Among the factors that may result in differences are MorphoSys' expectations regarding the clinical development of tafasitamab in previously untreated DLBCL, in combination with lenalidomide in the L-MIND study in r/r DLBCL, the clinical development of tafasitamab in combination with bendamustine versus rituximab and bendamustine in the B-MIND study in r/r DLBCL, the further clinical development of tafasitamab as well as interactions with regulatory authorities and expectations regarding regulatory filings and possible approvals for tafasitamab, MorphoSys' reliance on collaborations with third parties, estimating the commercial potential of its development programs and other risks indicated in the risk factors included in MorphoSys's Annual Report on Form 20-F and other filings with the US Securities and Exchange Commission. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. MorphoSys expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements, unless specifically required by law or regulation.

For more information, please contact:
MorphoSys AG

Dr. Sarah Fakih
Head of Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-26663
Sarah.Fakih@morphosys.com

Dr. Julia Neugebauer
Director Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-179
Julia.Neugebauer@morphosys.com

Dr. Verena Kupas
Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-26814
Verena.Kupas@morphosys.com

SOURCE: MorphoSys

ReleaseID: 571511

NEW YORK, NY / ACCESSWIRE / December 27, 2019 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.

Uniti Group Inc. (NASDAQGS:UNIT)

If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/uniti-group-inc-loss-submission-form?prid=5078&wire=1
Lead Plaintiff Deadline: December 30, 2019
Class Period: April 20, 2015 to February 15, 2019

Allegations against UNIT include that: (i) Uniti's financial results were not sustainable because its customer Windstream had defaulted on its unsecured notes; and (ii) as a result of the foregoing, Defendants' statements about Uniti's business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.

Baxter International Inc. (NYSE:BAX)

If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/baxter-international-inc-loss-submission-form?prid=5078&wire=1
Lead Plaintiff Deadline: January 24, 2020
Class Period: February 21, 2019 to October 23, 2019

Allegations against BAX include that: (1) certain intra-Company transactions, undertaken for the purpose of generating foreign exchange gains and losses, used foreign exchange rate conventions that were not in accordance with GAAP and enabled intra-Company transactions to be undertaken after the related exchange rates were already known; (2) the Company lacked effective internal control over financial reporting; (3) as a result, the Company's financial statements were misstated and would likely require correction or amendment; (4) due to the Company's internal investigation, Baxter would not be able to file its quarterly report for the period ending September 30, 2019, with the SEC on Form 10-Q in a timely manner; and (5) as a result of the foregoing, Defendants' statements about the Company's business and operations lacked a reasonable basis.

UP Fintech Holding Limited (NASDAQ:TIGR)

If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/up-fintech-holding-limited-loss-submission-form?prid=5078&wire=1
Lead Plaintiff Deadline: January 6, 2020
Class Period: all persons and entities that purchased or otherwise acquired: (a) Fintech American Depository Shares pursuant and/or traceable to the Company's initial public offering conducted on or about March 20, 2019; or (b) Fintech securities between March 20, 2019 and May 16, 2019.

Allegations against TIGR include that: (i) Fintech was experiencing a material decrease in commissions because of a negative trend related to risk-averse investors in the market; (ii) Fintech was unable to absorb costs associated with the rapid growth of its business and its status as a publicly listed company on a U.S. exchange; (iii) Fintech was incurring significant additional expenses related to, inter alia, employee headcount and employee compensation and benefits; (iv) all of the foregoing had led to Fintech significantly increasing operating costs and expenses; and (v) as a result, the documents filed by the Company in connection with the initial public offering were materially false and/or misleading and failed to state information required to be stated therein, and the Company's Class Period statements were likewise materially false and/or misleading.

To learn more contact Vincent Wong, Esq. either via email vw@wongesq.com or by telephone at 212.425.1140.

Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: vw@wongesq.com

SOURCE: The Law Offices of Vincent Wong

ReleaseID: 571510

NEW YORK, NY / ACCESSWIRE / December 27, 2019 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.

GDOT Shareholders Click Here: https://www.zlk.com/pslra-1/green-dot-corporation-loss-form?prid=5077&wire=1
UA Shareholders Click Here: https://www.zlk.com/pslra-1/under-armour-inc-loss-form?prid=5077&wire=1
AZZ Shareholders Click Here: https://www.zlk.com/pslra-1/azz-inc-loss-form?prid=5077&wire=1

* ADDITIONAL INFORMATION BELOW *

Green Dot Corporation (NYSE:GDOT)

GDOT Lawsuit on behalf of: investors who purchased May 9, 2018 – November 7, 2019
Lead Plaintiff Deadline: February 17, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/green-dot-corporation-loss-form?prid=5077&wire=1

According to the filed complaint, during the class period, Green Dot Corporation made materially false and/or misleading statements and/or failed to disclose that: (1) Green Dot's strategy to attract "high-value" long-term customers was at the expense of "one and done" customers; (2) Green Dot's "one and done" customers represented a significant source of revenues in its legacy segment; (3) consequently, Green Dot's strategy was self-sabotaging; and (4) as a result of the foregoing, Defendants' statements about its business and operations were materially false and misleading at all relevant times.

Under Armour, Inc. (NYSE:UA)

UA Lawsuit on behalf of: investors who purchased August 3, 2016 – November 1, 2019
Lead Plaintiff Deadline: January 6, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/under-armour-inc-loss-form?prid=5077&wire=1

According to the filed complaint, during the class period, Under Armour, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) Under Armour shifted sales from quarter to quarter to appear healthier, including to keep pace with their long-running year-over-year 20% net revenue growth; (2) undisclosed to the investing public, the Company had been under investigation by and cooperating with the U.S. Department of Justice and U.S. Securities and Exchange Commission since at least July 2017; and (3) as a result, Defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Azz, Inc. (NYSE:AZZ)

AZZ Lawsuit on behalf of: investors who purchased July 3, 2018 – October 8, 2019
Lead Plaintiff Deadline: January 3, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/azz-inc-loss-form?prid=5077&wire=1

According to the filed complaint, during the class period, Azz, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) the Company's internal controls over financial reporting were not effective; (2) the Company improperly implemented ASC 606 which resulted in improper revenue reconciliations; and (3) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

ReleaseID: 571509

NEW YORK, NY / ACCESSWIRE / December 27, 2019 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.

Sealed Air Corporation (NYSE:SEE)

If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/sealed-air-corporation-loss-submission-form?prid=5076&wire=1
Lead Plaintiff Deadline: December 31, 2019
Class Period: November 5, 2014 to August 6, 2018

Allegations against SEE include that: (a) Sealed Air had hired its auditor, E&Y, pursuant to a conflicted and improper process and in order to help facilitate defendants' efforts to engage in accounting fraud; (b) Sealed Air's deduction of $1.49 billion in connection with the Settlement was indefensible and done for the improper purpose of artificially inflating the Company's financial results; (c) Sealed Air had artificially inflated its earnings, cash flows, and operating income during the Class Period; (d) as a result of the above, Sealed Air's Class Period financial statements were materially false and misleading and not prepared in conformance with GAAP; and (e) as a result of the above, Sealed Air's statements regarding its financial results, business, and prospects were materially misleading.

Twitter, Inc. (NYSE:TWTR)

If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/twitter-inc-loss-submission-form?prid=5076&wire=1
Lead Plaintiff Deadline: December 30, 2019
Class Period: August 6, 2019 to October 23, 2019

The filed complaint alleges that defendants engaged in a scheme to deceive the market and a course of conduct that artificially inflated Twitter's common share price and operated as a fraud or deceit on purchasers of Twitter common stock by misrepresenting the Company's operating condition and future business prospects. The scheme was perpetrated by making positive statements about Twitter's business while defendants knew, or disregarded with deliberate recklessness, certain adverse facts. When defendants' prior misrepresentations were disclosed and became apparent to the market, the price of Twitter's common stock fell precipitously.

Merit Medical Systems, Inc. (NASDAQ:MMSI)

If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/merit-medical-systems-inc-loss-submission-form?prid=5076&wire=1
Lead Plaintiff Deadline: February 3, 2020
Class Period: February 26, 2019 to October 30, 2019

Allegations against MMSI include that: (a) the integrations of acquired companies Cianna Medical, Inc. and Vascular Insights, LLC, including their products, sales people, and R&D facilities, had caused operational disruptions and reduced sales and were months behind schedule; (b) sales of acquired company products had slowed substantially due to pre-acquisition pipeline fill, in particular for Vascular Insights products which, as late as July 2019, had zero orders during FY19; and (c) in light of the foregoing, the Company's reported financial guidance for FY19 and FY20 was made without a reasonable basis.

To learn more contact Vincent Wong, Esq. either via email vw@wongesq.com or by telephone at 212.425.1140.

Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: vw@wongesq.com

SOURCE: The Law Offices of Vincent Wong

ReleaseID: 571508

LOS ANGELES, CA / ACCESSWIRE / December 27, 2019 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against AZZ Inc. ("AZZ" or "the Company") (NYSE:AZZ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company's securities between July 3, 2018 and October 8, 2019, inclusive (the ''Class Period''), are encouraged to contact the firm before January 3, 2020.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. AZZ failed to maintain appropriate and effective controls on financial reporting. The Company's improper implementation of ASC 606 resulted in incorrect revenue reconciliations. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about AZZ, investors suffered damages.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
Cell: 424-303-1964
info@schallfirm.com

SOURCE: The Schall Law Firm

ReleaseID: 571505

LOS ANGELES, CA / ACCESSWIRE / December 27, 2019 / The Schall Law Firm, a national shareholder rights litigation firm, announces it has filed a class action lawsuit against Baxter International Inc. ("Baxter" or "the Company") (NYSE:BAX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company's securities between February 21, 2019 and October 23, 2019, inclusive (the ''Class Period''), are encouraged to contact the firm before January 24, 2020.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Baxter engaged in intra-Company transactions designed to generate gains from foreign exchanges that did not follow GAAP principles and were undertaken when the foreign exchange rates were already known. The Company failed to maintain effective controls on financial reporting. Based on the Company's internal investigation of these matters, it was not capable of filing a Form 10-Q quarterly report for the period ending September 30, 2019. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Baxter, investors suffered damages.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
Cell: 424-303-1964
info@schallfirm.com

SOURCE: The Schall Law Firm

ReleaseID: 571503

LOS ANGELES, CA / ACCESSWIRE / December 27, 2019 / The Schall Law Firm,a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Yunji Inc. ("Yunji" or "the Company") (NASDAQ:YJ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission."

Investors who purchased the Company's securities pursuant and/or traceable to the Company's Registration Statement issued in connection with its May 2019 initial public stock offering (the "IPO" or "Offering"), are encouraged to contact the firm before January 13, 2020.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Yunji shifted sales to its marketplace, a restructuring likely to disrupt the Company's relationships with suppliers. The change was also likely to have a negative impact on financial results. Based on these facts, the Company's public statements were false and materially misleading throughout the IPO period. When the market learned the truth about Yunji, investors suffered damages.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
Cell: 424-303-1964
info@schallfirm.com

SOURCE: The Schall Law Firm

ReleaseID: 571501

Helping his readers understand changes and advancements in technology, computer engineer Eliseo Delgado Jr. frequently breaks down complicated topics in his online articles. Here, he explains how the self-driving semis soon to hit American highways will vastly improve the distribution of goods across the country.

RIVERSIDE, CA / ACCESSWIRE / December 27, 2019 / Eliseo Delgado Jr. has seen first-hand how advances in technology like robotics, artificial intelligence, and the Internet of Things (IoT) have improved many professional processes. While a lot of people are worried that computers and machines are replacing jobs faster than we can create new ones, he believes modern society would not be able to function without their mechanical counterparts.

"Just look at how we rely on our smart devices today and how many jobs are only able to accomplish what they do with the use of sophisticated computers and programs," says Eliseo Delgado Jr. "The transportation and distribution industries are some of the weakest right now with plenty of positive changes coming down the line through the help of technology."

He believes the same tech advances allowing self-driving vehicles to drive on roads today will help automate a lot of processes in distribution and provide services for the trucking industry that haven't been tapped into before. The country is only able to distribute necessities like water, food, medical supplies and more to all fifty states because of drivers in the trucking industry. A large wave of retiring truck drivers–and very few stepping up to fill in their jobs–has caused the industry to consider creative options to stay afloat.

Self-driving vehicles are carefully crafted to monitor traffic and detect potential problems on the road. Their programming is capable of quick-response maneuvers to threats like vehicles merging into lanes or potential hazards in their path. Vehicles like Tesla cars are built to protect their own driver while keeping other drivers on the road safe. This same technology can be scaled up and used by heavy machinery like semis.

The over-the-road truck driving industry is a vital source of delivery for every product bought or sold in the country, so a lack of drivers would cause a tremendous setback everywhere. Self-driving vehicles have now been tasked with carrying heavy loads and large cargo from coast to coast, paving the way for automated semi-trucks in the future.

Self-driving technology has also been used for same-city deliveries by companies like Amazon, UPS, grocery stores, and others. Soon, self-driving semis will ensure that each state receives the goods its citizens need while hopefully reducing or eliminating the accidents caused by human drivers.

"People don't have to worry about self-driving trucks taking over people's jobs and leaving them nothing to do," says Eliseo Delgado Jr. "Human responsibilities will likely just shift elsewhere in the production line instead of requiring them to drive trucks, and this is only in response to a lack of candidates filling existing roles. The machines are just here to help us do the heavy lifting."

CONTACT:

Caroline Hunter
Web Presence, LLC
+1 7862338220

SOURCE: Web Presence, LLC

ReleaseID: 571499

LOS ANGELES, CA / ACCESSWIRE / December 27, 2019 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Sealed Air Corporation ("Sealed Air" or "the Company") (NYSE:SEE) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission."

Investors who purchased the Company's securities between November 5, 2014 and August 6, 2018, inclusive (the ''Class Period''), are encouraged to contact the firm before December 31, 2019.

We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Sealed Air improperly deducted $1.49 billion related to the settlement of asbestos liabilities from its taxes to artificially inflate its financial performance. The Company switched auditors to help facilitate this fraud. On August 6, 2018, the Company admitted that it had received a subpoena from the SEC related to the Company's accounting for taxes and financial disclosures. Based on these facts, the company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Sealed Air, investors suffered damages.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
Cell: 424-303-1964
info@schallfirm.com

SOURCE: The Schall Law Firm

ReleaseID: 571498

Former news journalist Karina Rusk has had an impressive career in broadcast news with reports featured on ABC, NBC, CBS, and PBS affiliate stations, in addition to contributions to CNN. She also makes community non-profits a priority as Rusk volunteers with and encourages support of the Boys and Girls Clubs of Monterey County, which empowers local youth.

MONTEREY, CA / ACCESSWIRE / December 27, 2019 / Karina Rusk has spent decades contributing to broadcast news stations and has demonstrated strong leadership in all her professional avenues. She's worked both as an award-winning healthcare marketing executive, based primarily out of Monterey, California and as a former broadcast news journalist, based primarily out of the San Francisco Bay Area. Her current work is focused on developing strategic communication plans and content for complex organizations and networks. She is considered an expert in public relations, media relations, government relations, marketing, health and wellness initiatives, and employee engagement.

In the past, Karina Rusk has donated her time to support various non-profit organizations such as Special Olympics, the Monterey County Reads program, created by The Panetta Institute for Public Policy, and the Boys & Girls Clubs of Monterey County. Through the Clubs, she upholds their mission to better the lives of youth in the county by raising awareness of the cause and volunteering in a variety of roles.

She's participated as emcee in the Boys and Girls Clubs of Monterey County Youth of the Year event, helping raise $160,000 in one evening to support the group's mission. The money raised was used to continue and improve programs that help uplift Monterey County youth and help provide them with valuable skills.

The mission of the Boy and Girls Club is to ‘inspire and empower the youth of Monterey County to realize their full potential to become responsible, healthy, productive and successful citizens.' The organization has been active in the county since 1968 and today operates two clubhouses that cater to an average of 500 children each day with high-quality programs provided by trained youth development professionals.

Many of the volunteers and supporters like Karina Rusk serve as trusted mentors and advocates for positive youth activities. Through an uplifting and fun environment, the Boys and Girls Club offers each child growth opportunities, recognition, and guidance from respected leaders. It's the vision of the organization to inspire youth to perform well in grade school, graduate high school, complete post-secondary education or training, and earn a livable wage in a productive career path.

Ron Johnson, President & CEO of the Boys and Girls Clubs of Monterey County, believes the caring staff is part of what makes the Clubs special to the many families the organization serves. By engaging leaders like Karina Rusk, he is able to ensure a culture of good character, integrity

CONTACT:

Caroline Hunter
Web Presence, LLC
+1 7862338220

SOURCE: Web Presence, LLC

ReleaseID: 571497